Feng Shen

784 citations
25 papers · 639 indexed · h-index 13
Topics
Cancer-related molecular mechanisms research (8 papers)MicroRNA in disease regulation (4 papers)RNA modifications and cancer (4 papers)
Partner nations
ChinaUnited StatesCanada

In The Last Decade

Feng Shen

25 papers receiving 629 citations

Peers

Feng Shen
Comparison fields: 5 of 76
  • Molecular Biology 373
  • Cancer Research 281
  • Oncology 103
  • Rheumatology 89
  • Immunology 58
Replace M. Byrne with:
M. Byrne United States
Toru Wakamatsu Japan
Richa Khatri United States
Vitor H. Teixeira United Kingdom
Leonardo D’Urso Italy
Akihiko Kobayashi Japan
Zenan Yuan China
Shao‐Hao Chen China
Cynthia E. Wilkins-Port United States
Sebastian Kłosek Poland
Feng Shen relative to M. Byrne United States M. Byrne's profile →
Citations per field
00.5×12.2×
M. Byrne · 1×
Citations per year

Countries citing papers authored by Feng Shen

Since Specialization
Citations

This map shows the geographic impact of Feng Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feng Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feng Shen more than expected).

Fields of papers citing papers by Feng Shen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Feng Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feng Shen. The network helps show where Feng Shen may publish in the future.

Co-authorship network of co-authors of Feng Shen

This figure shows the co-authorship network connecting the top 25 collaborators of Feng Shen. A scholar is included among the top collaborators of Feng Shen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Feng Shen. Feng Shen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 34
2 17
3 9
4 17
5 11
6 5
7 13
8 13
9 106
10 11
11 5
12
Expression of miR-221 in colon cancer correlates with prognosis.
36
13 49
14 53
15 10
16 1
17 2
18
Spontaneous complete necrosis of hepatocellular carcinoma: a case report.
17
19 4
20 38

About Feng Shen

Feng Shen is a scholar working on Cancer Research, Physiology and Molecular Biology, having authored 25 papers that have together received 639 indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (8 papers), MicroRNA in disease regulation (4 papers) and RNA modifications and cancer (4 papers). The work is most often cited by research in Cancer Research (281 citations), Rheumatology (89 citations) and Molecular Biology (373 citations). Feng Shen has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Manohar Ratnam, Xin Wang, James H. Freisheim, L E Gentry, Yifan Kang, Jin Wang, Tianfu Yu, Junxia Zhang, Yingyi Wang and Yongping You. Their work appears in journals such as Nature Medicine, Biochemistry and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026